Company research
TRINITY BIOTECH PLC
CIK 888721Updated Sep 24, 2026
SecurityTRIB · NASDAQ · adr
TRIB price & chart
Loading TradingView…
NASDAQ:TRIB on TradingView ↗About the company
We are a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. We develop, acquire, manufacture and market diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. We intend to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -31,216,000Source | -36,868,000Source | -41,002,000Source | 929,000Source |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodUSD | 10,000Source | -198,000Source | 61,000Source | 0Source |
| AdjustmentsForFinanceCostsUSD | 9,565,000Source | 11,053,000Source | 24,745,000Source | 7,097,000Source |
| AdjustmentsForFinanceIncomeUSD | 0Source | 1,171,000Source | 303,000Source | 1,223,000Source |
| AdjustmentsForIncomeTaxExpenseUSD | 486,000Source | -59,000Source | -192,000Source | -167,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 1,316,000Source | 2,069,000Source | 1,755,000Source | 1,100,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | 1,010,000Source | 238,000Source | -76,000Source | -251,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesUSD | -1,010,000Source | -312,000Source | 15,000Source | -1,619,000Source |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 8,000Source | 8,000Source | 1,293,000Source | 3,996,000Source |
| InterestPaidClassifiedAsOperatingActivitiesUSD | — | 0Source | 0Source | 11,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | 0Source | 0Source | 2,000Source | 1,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 2,503,000Source | 2,318,000Source | 2,761,000Source | 2,939,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | — | 0Source | 0Source | 1,764,000Source |
| ProceedsFromIssuingSharesUSD | 7,391,000Source | 0Source | 25,336,000Source | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | 9,659,000Source | 1,901,000Source | 4,876,000Source | 6,879,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 28,815,000Source | 31,152,000Source | 29,166,000Source | 24,683,000Source |
| Total RevenueUSD | 61,555,000Source | 56,832,000Source | 74,779,000Source | 92,965,000Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.13Source | 0.13Source | 0.13Source | 0.13Source |
| AuditorsRemunerationForTaxServicesUSD | 1,082,000Source | 861,000Source | 888,000Source | 549,000Source |
| AverageEffectiveTaxRatenumber | -0.02Source | -0Source | -0Source | -0.24Source |
| CurrentTaxExpenseIncomeUSD | 21,000Source | 0Source | -331,000Source | -511,000Source |
| DeferredTaxExpenseIncomeUSD | 201,000Source | -323,000Source | 83,000Source | 37,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossUSD | -683,000Source | 323,000Source | -83,000Source | 37,000Source |
| DepreciationAndAmortisationExpenseUSD | 204,000Source | 0Source | — | 39,000Source |
| DepreciationRightofuseAssetsUSD | — | 0Source | 34,000Source | 27,000Source |
| EmployeeBenefitsExpenseUSD | 30,152,000Source | 28,841,000Source | 28,025,000Source | 30,686,000Source |
| FinanceCostsUSD | 9,565,000Source | 11,053,000Source | 24,745,000Source | 7,097,000Source |
| FinanceIncomeUSD | 0Source | 1,171,000Source | 303,000Source | 1,223,000Source |
| GrossProfitUSD | 21,441,000Source | 19,450,000Source | 22,048,000Source | 38,077,000Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | 1,596,000Source | 5,833,000Source | 4,624,000Source | 3,853,000Source |
| ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossUSD | 1,408,000Source | 11,105,000Source | 5,839,000Source | 6,944,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | 486,000Source | -59,000Source | -192,000Source | -178,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 592,000Source | 624,000Source | 657,000Source | 815,000Source |
| OtherIncomeUSD | 40,000Source | 138,000Source | 0Source | 0Source |
| OtherOperatingIncomeExpenseUSD | -1,787,000Source | 141,000Source | 343,000Source | 4,672,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansUSD | 451,000Source | 508,000Source | 352,000Source | 352,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | 451,000Source | 507,609Source | 352,000Source | 352,000Source |
| ProfitLossAttributableToOwnersOfParentUSD | -31,789,000Source | -24,018,000Source | -41,009,000Source | 875,000Source |
| ProfitLossBeforeTaxUSD | -30,730,000Source | -36,927,000Source | -41,194,000Source | 751,000Source |
| ProfitLossFromOperatingActivitiesUSD | -21,165,000Source | -27,045,000Source | -16,752,000Source | 6,625,000Source |
| ResearchAndDevelopmentExpenseUSD | 4,543,000Source | 4,379,000Source | 4,138,000Source | 4,497,000Source |
| TaxRateEffectOfForeignTaxRatesnumber | 0.07Source | -0.08Source | -0.08Source | -0Source |